Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of “Hold” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average rating of “Hold” from the eight ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $6.75.

Several research firms recently commented on INO. Piper Sandler reissued an “overweight” rating and set a $6.00 target price (up from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. HC Wainwright reaffirmed a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. Citigroup reissued a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th. UBS Group restated an “overweight” rating on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research report on Monday, December 29th.

Institutional Trading of Inovio Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. MCF Advisors LLC acquired a new position in shares of Inovio Pharmaceuticals in the third quarter worth about $26,000. SG Americas Securities LLC acquired a new position in Inovio Pharmaceuticals in the 3rd quarter worth approximately $27,000. Stephens Inc. AR purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth approximately $32,000. Focus Partners Wealth purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth approximately $33,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the period. 26.79% of the stock is owned by hedge funds and other institutional investors.

More Inovio Pharmaceuticals News

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Neutral Sentiment: Multiple law firms are soliciting Inovio investors and reminding shareholders of an April 7, 2026 deadline to seek lead‑plaintiff status in a securities class action covering purchases between Oct. 10, 2023 and Dec. 26, 2025; these notices increase the pool of potential claimants and keep litigation front‑of‑mind for investors. Faruqi & Faruqi Deadline Notice Rosen Law Firm Notice Glancy Prongay Wolke & Rotter Notice
• Negative Sentiment: Levi & Korsinsky highlights alleged misrepresentations tied to the company’s Cellectra device manufacturing practices — this targets a core aspect of Inovio’s delivery technology and could heighten regulatory and litigation exposure. Levi & Korsinsky Article
• Negative Sentiment: A widely read retail/investor outlet published a bearish piece framing INO as highly risky and questioning whether the stock could head to zero — such negative coverage can amplify selling pressure from retail and institutional holders. Motley Fool Article
• Negative Sentiment: Additional plaintiff‑solicitation notices (DJS Law Group, Schall Law Firm and others) reinforce the same class‑action timeline and encourage shareholders to pursue lead‑plaintiff roles — increases probability of consolidated, high‑profile litigation. DJS Law Group Notice Schall Law Firm Notice

Inovio Pharmaceuticals Stock Up 4.6%

Shares of Inovio Pharmaceuticals stock opened at $1.81 on Thursday. The business has a fifty day simple moving average of $1.75 and a 200-day simple moving average of $2.06. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $2.98. The firm has a market cap of $120.78 million, a price-to-earnings ratio of -0.70 and a beta of 1.72.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.